Cipla (CIPLA) Q3 24/25 earnings summary

Executive summary

• Achieved strong revenue and profitability growth in Q3FY25, celebrating 90 years with a focus on innovation, global healthcare access, and a resilient, diversified business model.

• Maintained leadership in chronic therapies in India, expanded innovative product offerings, and advanced ESG initiatives, including Zero Waste to Landfill and high DJSI rankings.

• Unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2024 were approved and released, with the Board meeting held on 28 January 2025.

• The results have been reviewed by the Audit Committee and received an unmodified review conclusion from statutory auditors.

Financial highlights

• Achieved highest-ever quarterly revenue of INR 7,073 crore (₹7,072.97 crore), up 8.1% year-over-year, with EBITDA at INR 1,989 crore and net profit at INR 1,574.59 crore.

• EBITDA margin reached 28.1%, up 184 bps year-over-year; PAT margin at 22.2% (up 617 bps); gross margin stood at 68%.

• R&D spend was INR 360 crore, 5.1% of revenue.

• Net cash equivalent balance as of December 31, 2024, was INR 8,947 crore, with debt (including lease liability) at INR 466 crore.

• Other income for the quarter included ₹67 crore from a one-time legal settlement.

Outlook and guidance

• FY25 EBITDA is trending above earlier guidance of 24.5%-25.5%; ROIC remains strong at 30%.

• FY26 revenue growth expected, with key launches (Advair, Abraxane) anticipated in H2 FY26; further guidance on profitability to be provided post-budget.

• Chronic mix in India improved to 61.5% year-over-year; trade generics growth trajectory restored.

• The company expects a favorable outcome in ongoing litigation with the National Pharmaceutical Pricing Authority and has not made provisions for related demand notices.